Kumpulainen Eero J, Hirvikoski Pasi P, Johansson Risto T
Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
Acta Oncol. 2008;47(1):120-3. doi: 10.1080/02841860701518074.
The aim of the study is to report the long-term outcome and secondary tumours of early breast cancer patients of adjuvant CNF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) chemotherapy. One hundred and ninety four patients, 185 primary early breast cancer and nine locoregionally recurrent breast cancer patients, were entered onto the trial between May 1986 and November 1993. The therapies included surgery, radiation therapy, adjuvant CNF chemotherapy, and tamoxifen according to hormonal status. Some of patients were treated twice with CMF (methotrexate). The median follow-up time was 12.9 years. Eighty nine (48%) primary breast cancers relapsed, and six locoregional breast cancers relapsed. After 5-10 years the relapse incidence decreased notably. Eighty three patients died of breast cancer, and nine of other causes. Two cases of leukemia, six cases of skin cancer, two cases of Hodgkin's disease, two cases of meningioma, and two cases of endometrial cancer were observed. This article confirms the feasibility of adjuvant CNF for early breast cancer patients. Questions of possible causability of secondary cancer have yet to be explored.
本研究的目的是报告接受辅助性CNF（环磷酰胺、米托蒽醌和5-氟尿嘧啶）化疗的早期乳腺癌患者的长期预后及继发性肿瘤情况。194例患者，其中185例原发性早期乳腺癌患者和9例局部区域复发性乳腺癌患者，于1986年5月至1993年11月期间进入该试验。治疗方法包括手术、放射治疗、辅助性CNF化疗以及根据激素状态使用他莫昔芬。部分患者接受了两次CMF（甲氨蝶呤）治疗。中位随访时间为12.9年。89例（48%）原发性乳腺癌复发，6例局部区域乳腺癌复发。5至10年后复发率显著下降。83例患者死于乳腺癌，9例死于其他原因。观察到2例白血病、6例皮肤癌、2例霍奇金病、2例脑膜瘤和2例子宫内膜癌。本文证实了辅助性CNF用于早期乳腺癌患者的可行性。继发性癌症可能的因果关系问题尚待探索。
